Skip to main content

The medicines business | A question to investigate

From a changed document to a clear next question

A regulatory update is easy to circulate and harder to interpret. Does it affect this product, this authorisation or this planned change? What needs review now, and who can determine the answer? NEUVIOR is interested in the preparation between a new official publication and the accountable regulatory assessment. The aim is to make relevance and uncertainty clearer without pretending that an automated summary can determine an organisation’s obligations.

Film credits

In the conversation.

NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.

University of Warwick IATL | AI Ethics NowpharmaphorumTechRadar ProET PharmaFinancial TimesPharmaceutical TechnologyPharmaTimesManufacturing ChemistDigital HealthDaily BusinessTheBusinessDesk.comStartups MagazineInsider MediaYorkshire PostYork PressBusinessCloud

Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.

The inbox is not the decision process

Teams can receive many alerts while still missing the connection to an active project. The problem may be ownership rather than information volume. A useful triage process links the official change to a defined portfolio, the type of decision it could affect and the person authorised to assess it. It should distinguish a confirmed impact from a reason to investigate. An alert saying important is less useful than a traceable question explaining why review may be required.

Keep source status and dates visible

MHRA’s variations guidance distinguishes categories of marketing-authorisation changes and is updated over time (MHRA, n.d.). Its GxP data-integrity publication provides context for dependable records (MHRA, n.d.). These sources concern different responsibilities. A proposed regulatory-intelligence study would retain original publication and update dates, version history and direct source links. It would not treat a consultation, draft or historical document as a current final requirement simply because the wording appears relevant.

Relevance depends on product context

The same update may affect one product’s manufacturing change and have little bearing on another project. A triage brief therefore needs a permitted description of the product, authorisation route and change under consideration. Confidential detail should be limited to what the task requires. Where essential context is unavailable, the output should ask for specialist review rather than infer applicability. That distinction protects both the usefulness of the alert and the authority of the regulatory team.

A relevance question with an owner

The proposed output would connect a source change to the product context that makes it potentially relevant and identify the reviewer who can determine its impact. Where context is missing, it would say which fact is needed. That supports a focused regulatory discussion without turning a preliminary relevance assessment into an asserted obligation.

A public decision brief | An illustrative example

Open the question.
Inspect the reasoning.

Choose a business question, then look beneath its claim. See what a public source supports, what depends on the local setting and what a useful next step could be.

A medicines or implementation team considering an AI-supported evidence review.

Would a quicker review make the decision better?

The interesting question is the complete piece of work: finding relevant material, checking it, correcting the draft and reaching an accountable decision.

A proposition to investigate

Less preparation. The same ability to challenge.

An evidence-review approach could be useful if it reduces avoidable preparation while preserving source access, relevant qualifications and professional checking. That is the proposed value to test. No time reduction, accuracy improvement or customer result is asserted in this example.

The proposition is constructed for this public brief. It is not a published finding about PHARMORIS.

What the next brief would contain

A decision someone
can commission.

The decision
Whether one defined review task merits an agreed evaluation.
The comparator
The team's existing complete review process, including checking and corrections.
The evidence
Representative cases, source records, reviewer decisions, complete-task effort and exceptions.
Stop or redesign
Stop or redesign if source checking weakens, errors are unacceptable or the complete task offers insufficient value.

Constructed public example | Not PHARMORIS-generated software output or a measured customer result.

Keep this example brief

A bounded proposed evaluation

NEUVIOR could explore a small set of official updates against a defined, approved portfolio description. The comparator would be the organisation’s current alert-and-review process. A proposed PHARMORIS brief would be assessed for correct source status, relevance questions, missing context and routing to the appropriate reviewer. Historical cases could be used with their original dates preserved, ensuring that information published later does not quietly improve the experimental result through hindsight.

What the comparison should measure

Candidate outcomes include relevant updates correctly identified for review, irrelevant alerts that consume attention, source-version errors and the time required to establish ownership. The evaluation should assess whether a reviewer can reproduce the reasoning from the linked source. It should not count the quantity of alerts as value. Nor should a successful triage exercise be described as regulatory compliance or as proof that a tool can prepare and submit an acceptable application.

Conditions for stopping or narrowing

The study would pause if the portfolio context is too incomplete to assess relevance or if reviewers cannot distinguish source text from a proposed interpretation. It would stop if experimental output is used to decide submission obligations without qualified review. Another failure is excessive noise: a system that makes every change appear material can reduce attention to the changes that need it. The next step may be a narrower topic, a better ownership map or no further development.

A practical regulatory discussion

Bring one category of updates that repeatedly causes difficult internal routing or interpretation. Explain which projects could be affected and how the team currently determines relevance. We can discuss a bounded triage comparison and the evidence required to judge it. The commercial purpose is to support focused regulatory attention with a clear account of source, context and responsibility, while all conclusions about requirements and submissions remain with the organisation’s qualified regulatory decision-makers.

Sources and scope

MHRA | Variations to marketing authorisations | MHRA | GxP data integrity

Discuss regulatory-change triage

MHRA (n.d.) Variations to marketing authorisations. Available at: https://www.gov.uk/guidance/medicines-apply-for-a-variation-to-your-marketing-authorisation (Accessed: 14 October 2026).

MHRA (n.d.) GxP data integrity. Available at: https://www.gov.uk/government/publications/guidance-on-gxp-data-integrity (Accessed: 14 October 2026).

Another useful angle.

NEWSPerspectives & features
Open newsroom